NCT05092958 2026-05-13Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyNational Cancer Institute (NCI)Phase 3 Active not recruiting654 enrolled